Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (CLOVER-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03478462
Recruitment Status : Recruiting
First Posted : March 27, 2018
Last Update Posted : December 2, 2021
Sponsor:
Information provided by (Responsible Party):
Cellectar Biosciences, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : December 2024